-
Capital, M&A & Industry Strategy5 days agoCan Benelux turn scientific strength into larger biotech scale?
Belgium and the Netherlands have built some of Europe's strongest life sciences ecosystems, powered by leading research institutions and a growing pool of experienced biotech talent....
-
Capital, M&A & Industry Strategy6 days agoBrainChild Bio masterminds $116M series A for CAR-T’s pivotal push in pediatric brain cancer
A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.
-
Capital, M&A & Industry Strategy7 days agoGerontology group backs updated immunization guidance
The Gerontological Society of America has thrown its institutional weight behind a sweeping new review of respiratory vaccine evidence, endorsing findings released on September 2, 2026...
-
Capital, M&A & Industry Strategy1 week agoGan & Lee’s first big cross-border deal aids Menarini push into obesity
BIOCENTURY | DEALSGAN & LEE’S FIRST BIG CROSS-BORDER DEAL AIDS MENARINI PUSH INTO OBESITYData for twice-monthly GLP-1R agonist were competitive vs. market leaders Zepbound and Wegovy
-
Capital, M&A & Industry Strategy1 week agoSuperluminal’s $60M series B to drive first clinical study: Finance Report
BIOCENTURY | FINANCESUPERLUMINAL’S $60M SERIES B TO DRIVE FIRST CLINICAL STUDY: FINANCE REPORTPlus: Gene insertion company Typewriter launches with series A; Electra files for NASDAQ listing;...
-
Capital, M&A & Industry Strategy1 week agoMedicines Discovery Catapult Backs Two U.K. Biotech Companies Tackling Chronic Diseases
Medicines Discovery Catapult provided its investment and expert support to help two biotech companies accelerate the development of new treatments for a range of autoimmune, inflammatory,...
-
Capital, M&A & Industry Strategy1 week agoThis week in charts: China deals, stock flatlines and Lilly’s M&A spree
Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other...
-
Capital, M&A & Industry Strategy1 week agoMerck adds 53 to New Jersey chopping block
Follow along as BioSpace tracks job cuts and restructuring initiatives.
-
Capital, M&A & Industry Strategy1 week agoBiotech is back, with H1 progress smoothing glide path through end of year: Truist
With M&A rising, venture capital returning and policy risks easing, biotech is on a positive trajectory following a prolonged post-pandemic slump, Truist Securities declared after a...
-
Capital, M&A & Industry Strategy1 week agoTop biotech deals in August 2026
Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease. The post...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
